September 19, 2016

FaegreBD Represents CoLucid Pharmaceuticals in Public Offering

Faegre Baker Daniels represented CoLucid Pharmaceuticals, Inc. in its $74.8 million public offering. CoLucid’s common stock trades on the NASDAQ Global Market under the symbol “CLCD.”   

CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. The company is headquartered in Cambridge, Massachusetts.

Piper Jaffray & Co. and Barclays Capital Inc. acted as joint book-running managers for the offering. Stifel acted as lead manager for the offering, and Ladenburg Thalmann acted as co-manager for the offering.

Jonathan Zimmerman, a partner in FaegreBD’s corporate practice, led the team representing CoLucid, along with Dan Boeglin, Christine Long, Miranda Hirner, Ryan Woessner and Raxit Shah.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.